XOMA Corporation (NASDAQ:XOMA) has been assigned a consensus recommendation of “Hold” from the six research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $27.33.
A number of analysts have recently commented on XOMA shares. Zacks Investment Research raised shares of XOMA Corporation from a “sell” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $38.00 price objective on shares of XOMA Corporation in a research report on Tuesday. Wedbush reissued a “hold” rating on shares of XOMA Corporation in a research report on Monday, August 14th. Finally, ValuEngine raised shares of XOMA Corporation from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 12th.
Shares of XOMA Corporation (XOMA) traded up 1.48% on Friday, hitting $23.93. 178,056 shares of the stock traded hands. XOMA Corporation has a 52 week low of $3.96 and a 52 week high of $24.92. The firm’s 50 day moving average is $18.52 and its 200 day moving average is $9.80. The firm’s market capitalization is $181.82 million.
COPYRIGHT VIOLATION WARNING: This story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2017/10/27/xoma-corporation-xoma-receives-17-00-average-price-target-from-analysts.html.
A hedge fund recently raised its stake in XOMA Corporation stock. California Public Employees Retirement System raised its stake in XOMA Corporation (NASDAQ:XOMA) by 95.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,780 shares of the biotechnology company’s stock after purchasing an additional 10,640 shares during the period. California Public Employees Retirement System owned 0.29% of XOMA Corporation worth $123,000 at the end of the most recent quarter. Institutional investors and hedge funds own 32.92% of the company’s stock.
About XOMA Corporation
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.